BioSpace News Archive

Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development

Enables Itamar to leverage Spry’s existing FDA-cleared technology to bring to market the first device for continuous remote patient monitoring (RPM) of sleep apnea Adds the capability to monitor the longer-term accumulated disease burden of sleep apnea to complement the single night diagnostics commonly used today, including the Company’s existing WatchPAT™ device Paves the way for an end-to-end digital care pathway that can further expand Itamar’s presence in obstructive sleep apnea (OSA)

Luminex Corporation announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and full-year revenue of approximately $417M, up approximately 25% over the full year 2019.

Accelerate Diagnostics, Inc. announced preliminary financial results for the fourth quarter and full year ending December 31, 2020.

MidWest Eye Center, a leading multispecialty ophthalmology provider in the Greater Cincinnati Tri-State Area, has affiliated with EyeSouth Partners, a portfolio company of Shore Capital Partners.

Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues.

Amneal Pharmaceuticals, Inc. and Kashiv BioSciences LLC announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC, a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505 drugs.

Opticyte Secures $4.6 Million in Funding to Develop First Cell O 2 Monitor for Reducing Organ Failure Opticyte obtains funding from a $2.9MM SBIR Phase IIB grant and completes a $1.7MM seed round to launch first observational trial of Opticyte Cell O 2 Monitor

Effective January 4, 2021, North American Partners in Anesthesia will deliver anesthesia services to the Piedmont Orthopedics | OrthoAtlanta ambulatory surgery center in Fayetteville, Georgia.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today an outline of its strategic priorities and action plan for 2021. The priorities for 2021 fall into four key areas: Near term focus on rare neurodegenerative diseases, especially ALS